A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery

被引：52

作者：

Sutter, Jennifer A. ^{[1
,2
]}

Kwan-Morley, Jennifer ^{[3
]}

Dunham, Jon ^{[3
]}

Du, Yang-Zhu ^{[1
,2
]}

Kamoun, Malek ^{[1
,2
]}

Albert, Daniel ^{[4
]}

Eisenberg, Robert A. ^{[3
]}

Prak, Eline T. Luning ^{[1
,2
]}

机构：

[1] Univ Penn, Sch Med, Dept Pathol, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Lab Med, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA

[4] Dartmouth Hitchcock Med Ctr, Rheumatol Sect, Lebanon, NH 03756 USA

来源：

CLINICAL IMMUNOLOGY | 2008年 / 126卷 / 03期

关键词：

B cells; systemic lupus; erythematosus; autoimmunity; human; transitional B cells; immunophenotype;

D O I：

10.1016/j.clim.2007.11.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis generated three candidate biomarkers for lymphocyte monitoring in patients with autoimmune disease who are treated with rituximab: circulating transitional B cells, the K: ratio and natural killer cells. Further refinement of these potential biomarkers may lead to a better understanding of the rote of B cells in disease pathogenesis and a more rational use of B cell depletion therapies. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：282 / 290

页数：9

共 30 条

[11] B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus [J].

Eisenberg, R ;

Albert, D .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (01) :20-27

[12]

GEARY WA, 1993, MODERN PATHOL, V6, P155

[13] B cell abnormalities in systemic lupus erythematosus [J].

Grammer, AC ;

Lipsky, PE .

ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 4) :S22-S27

[14] Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients [J].

Green, MRJ ;

Kennell, ASM ;

Larche, MJ ;

Seifert, MH ;

Isenberg, DA ;

Salaman, MR .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 141 (01) :165-173

[15]

Isenberg DA, 2006, J RHEUMATOL, V33, P24

[16] Turnover and proliferation of NK cells in steady state and lymphopenic conditions [J].

Jamieson, AM ;

Isnard, P ;

Dorfman, JR ;

Coles, MC ;

Raulet, DH .

JOURNAL OF IMMUNOLOGY, 2004, 172 (02) :864-870

[17] T and B lymphocytes exert distinct effects on the homeostasis of NK cells [J].

Jeannet, Gregoire ;

Coudert, Jerome D. ;

Held, Werner .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (10) :2725-2734

[18] Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus [J].

Ju, Shaoqing ;

Zhang, Donglei ;

Wang, Yueguo ;

Ni, Hongbing ;

Kong, Xiantao ;

Zhong, Renqian .

CLINICAL BIOCHEMISTRY, 2006, 39 (12) :1131-1137

[19] B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients [J].

Leandro, MJ ;

Cambridge, G ;

Edwards, JC ;

Ehrenstein, MR ;

Isenberg, DA .

RHEUMATOLOGY, 2005, 44 (12) :1542-1545

[20] Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis [J].

Leandro, MJ ;

Cambridge, G ;

Ehrenstein, MR ;

Edwards, JCW .

ARTHRITIS AND RHEUMATISM, 2006, 54 (02) :613-620

← 1 2 3 →